Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: A [123I]epidepride single photon emission tomography (SPET) study

Psychopharmacology

Volumn 150, Issue 2, 2000, Pages 132-140

  Bigliani, V ^a   Mulligan, R S ^b   Acton, P D ^b,d   Ohlsen, R I ^a   Pike, V W ^c   Ell, P J ^b   Gacinovic, S ^b   Kerwin, R W ^a   Pilowsky, L S ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antipsychotic drug; Dopamine D2 D3 receptor; Epidepride; Olanzapine; Schizophrenia; Single photon emission tomography

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE; FLUPENTIXOL; FLUPHENAZINE DECANOATE; IODINE 123; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IN VIVO STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BENZODIAZEPINES; CORPUS STRIATUM; FEMALE; HUMANS; IMIDAZOLES; INDOLES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PIRENZEPINE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033946969     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000435     Document Type: Article

References (62)

1. Abnormal Involuntary Movements Scale (AIMS) (1974) Alcohol, Drug Abuse, and Mental Health Administration. Department of Health, Education and Welfare, Washington, DC
2. Barnes T (1989) A Rating Scale for Drug-Induced Akathisia. Br J Psychiatry 154:672-676
3. Beasley CM, Tollefeson G, Tran P, Satterlee W, Sanger T, Hamilton S (1997) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123
4. Bigliani V, Mulligan RS, Acton PD, Gacinovic S, Ell PJ, Kerwin RW, Pilowsky LS (1998) Different patterns of D2/D2-like receptor blockade in the temporal cortex and the striatum by typical antipsychotics: an [123I]-epidepride SPET study. Schizophrenia Research, Special Issue: Abstracts of the Ninth Biennial Winter Workshop on Schizophrenia, 29:165
5. Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C, Kerwin RW, Pilowsky LS (1999) In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs - a [123I]epidepride single photon emission tomography (SPET) study. Br J Psychiatry 175:231-238
6. 2 blockade by typical and atypical neuroleptics. Lancet 339:497
7. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropharmacology 14:87-96
8. Camps M, Cortes R, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in human brain. Autoradiographic distribution of D2 sites. Neuroscience 28:275-290
9. Damasio H, Damasio AR (1989) Lesion analysis in neuropsychology. Oxford University Press, New York
10. Decker C, Korchounov A, Broich K, Mameros A, Mende T (1998) Striatal dopamine D2 receptor occupancy by atypical neuroleptics in patients with schizophrenia. Eur J Nucl Med 25:1076
11. Dresel S, Mager T, Rossmuller B, Tatsch K, Hahn K (1998) [I-123]IBZM SPECT for assessment of striatal D2 receptor binding in vivo under treatment with olanzapine, a new atypical antipsychotic drug. Eur J Nucl Med 25:947
12. Farde L, Wiesel A, Nordstrom AL, Sedvall G (1989) D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31
13. Farde L, Wiesel F-A, Stone-Elander S et al. (1990) D2 dopamine receptors in neuroleptic naive schizophrenic patients. Arch Gen Psychiatry 47:213-219
14. Farde L, Nordstrom AL, Wiesel A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Arch Gen Psychiatry 49:538-543
15. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C (1997a) A PET study of 11C FLB-457 binding to extrastriatal D2 dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133: 396-404
16. Farde L, Mack RJ, Nyberg S, Halldin C (1997b) D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int Clin Psychopharmacol 12 Suppl 1:S3-S7
17. Fujita M, Seibyl JP, Verhoeff NPLG, Ichise M, Baldwin RM, Zoghbi SS, Burger C, Staley JK, Rajeevan N, Charney DS, Innis RB (1999) Kinetic and equilibrium analyses of [123I] epidepride binding to striatal and extrastriatal dopamine D2 receptors. Synapse 34:290-304
18. Fulton B, Goa KL (1997) Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychosis. Drugs 53:281-298
19. Goldsmith SK, Shapiro RM, Joyce JN (1997) Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia: a postmortem study. Arch Gen Psychiatry 54:649-658
20. Guy W (1976) ECDEU assessment manual for psychopharmacology. US Dept. of Health and Human Services publication (ADM) 76-338, Rockville, Md., pp 217-222
21. Hall H, Sedvall G, Magnusson O, Koopp J, Halldin C, Farde L (1994) Distribution of D1 dopamine and D2 dopamine receptors, dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256
22. Hall H, Farde L, Halldin C, Hurd Y, Pauli S, Sedvall G (1996) Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using 125I-epidepride. Synapse 23:115-123
23. Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, Rajeevan N, Charney DS, Innis RB (1999) Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. J Nucl Med 40:1902-1912
24. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C] raclopride binding. J Cereb Blood Flow Metab 18:941-949
25. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D-2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928
26. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale. Schizophr Bull 13:261-276
27. Kerwin RW (1994) The new atypical antipsychotics. Br J Psychiatry 164:141-148
28. Kessler RM, Scott Mason N, Votaw JR, De Paulis T, Clanton JA, Sib Ansari M, Schmidt DE, Manning RG, Bell RL (1992) Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 223:105-107
29. Kessler RM, Whetsell WO, Sib Ansari M, Votaw JR, Paulis T de, Clanton JA, Schmidt DE, Scott Mason N, Manning RG (1993) Identification of extrastriatal dopamine D2 receptors in post mortem human brain with 125I-epidepride. Brain Res 609: 237-243
30. Kuikka JT, Akerman KK, Hiltunen J, Bergstrom KA, Rasanen P, Vanninen E, Halldin C, Tiihonen J (1997) Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. Eur J Nucl Med 24:483-487
31. Lidow MS, Goldman-Rakic PS (1994) A common action of clozapine, haloperidol and remoxipride on D1-and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci 91:4353-4356
32. Lidow MS, Williams GV, Goldman-Rakic PS (1998) The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci USA 19:136-140
33. Lieberman JA (1996) Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 57 [Suppl 11]:68-71
34. Malmberg Å, Jackson DM, Eriksson A, Mohell N (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2a, D2b and D3 receptors. Mol Pharmacol 43:749-754
35. 76Br bromospiperone in untreated schizophrenic patients. Am J Psychiatry 147:44-50
36. Meltzer HY, Park S, Kessler R (1999) Cognition, schizophrenia and the atypical antipsychotic drugs. Proc Natl Acad Sci USA 96:13591-13593
37. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
38. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioural pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262:545-551
39. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine, and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
40. Nordstrom A-L, Farde L, Halldin C (1993) High 5HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365-367
41. Nordstrom AL, Nyberg S, Olsson H, Farde L (1998) Positron emission tomography finding of high striatal D2 receptor occupancy in olanzapine treated patients. Arch Gen Psychiatry 55:283-284
42. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B (1993) 5HT2 and D2 dopamine receptor occupancy in the living human brain of risperidone. Psychopharmacology 110:265-272
43. Nyberg S, Farde L, Halldin C (1997) A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7
44. Pickar D (1995) Prospects for pharmacotherapy of schizophrenia. Lancet 346:557-562
45. Pickar D, Tung-Ping Su, Weinberger DR, Coppola R, Malhotra AK, Knable M, Sam Lee K, Gorey J, Bartko J, Breier A, Hsiao J (1996) Individual variation in D2 dopamine receptor occupancy in clozapine treated patients. Am J Psychiatry 153:1571-1578
46. Pilowsky LS, Costa DC, Ell PJ, Murray R, Verhoeff N, Kerwin RW (1992) Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340:199-202
47. Pilowsky LS, Costa D, Ell P, Murray R, Verhoeff N, Kerwin RW (1994) D2 dopamine receptor binding in the basal ganglia of antipsychotic free schizophrenic patients - an 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 164:16-26
48. Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 124:148-153
49. Pilowsky LS, Mulligan R, Acton P, Costa D, Ell P, Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490-491
50. Pilowsky LS, Bigliani V, Mulligan RS, Acton PD, Pike V, Ell PJ, Gacinovic S, Kerwin RW (1998) Clozapine preferentially occupies limbic cortical D2/D3 receptors in vivo - a 123I epidepride SPET (single photon emission tomography) study. J Psychopharmacol 12 [Suppl A]:A53
51. Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deecke L, Podreka I, Brucke T (1997) Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 38:1711-1717
52. Raedler TJ, Knable MB, Lafague T, Pickar D, Weinberger DR (1998) Striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Schizophr Res 29:166
53. Seibyl J (1995) Development of SPET as a tool for neuropsychopharmacological research. In: Kerwin RW, Dawbarn D, McCulloch J, Tamminga C (eds) Neurobiology and psychiatry: neuroimaging, vol 3. Cambridge University Press, Cambridge, UK
54. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson A, Christensen BK, Seeman P (2000) Increase in dopamine D2 receptor binding following long-term treatment with neuroleptics in humans. Schizophr Res 41:237
55. Simpson GH, Angus JWS (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand Suppl 212:11-19
56. Sokoloff P, Giros B, Martres MP (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151
57. Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466-474
58. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM (1997) Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58:205-211
59. Travis MJ, Busatto GF, Pilowsky LS, Kerwin RW, Mulligan RS, Gacinovic S, Costa DCC, Ell PJ, Mertens J, Terriere D (1997) Serotonin 5-HT2a occupancy in vivo and response to the new antipsychotics olanzapine and sertindole. Br J Psychiatry 171: 290-291
60. Travis MJ, Busatto GF, Pilowsky LS, Mulligan RS, Gacinovic S, Acton PD, Costa DCC, Mertens J, Terriere D, Ell PJ, Kerwin RW (1998) Typical antipsychotics lead to 5HT2a receptor blockade in vivo in schizophrenic patients: initial single photon emission tomography findings. Schizophr Res 29:171
61. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
62. Xiberas X, Martinot JL, Pailliere-Martinot ML, Mallet L, Attar-Levy D, Sabran V, Loc'h C, Maziere B (1999) In vivo interactions of antipsychotic drugs with the extrastriatal D2 dopamine receptors. Schizophr Res 36:249